Promote a healthier life for humankind through advancements in science Science-based Benefit the patients with high-quality medication as we determined to innovate Innovation-driven Build a leading global biopharmaceutical group to serve more Going Global Fulfill social responsibilities through accountable actions Embrace SocialResponsibilities Explore who we are About us Innovation is the core of our development strategy Partnering We are actively looking for synergistic partnerships Walk into Hengrui Est. 1970 Marketed Innovative Products in China 10 SH 600276 Est. 1970 Marketed Innovative Products in China 8 SH 600276 Pipeline Our innovative pipeline covers the most of major therapeutic areas and continues to grow Pipeline Our innovative pipeline covers the most of major therapeutic areas and continues to grow Investor Enhance communication between our company and investors Media Camrelizumab11 Media 3Safety and immunogenicity Media NMPA approves a new indication of camrelizumab: combined with chemotherapy as 1L treatment for NPC
